CHAPTER 118 — REFERENCES

1. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following 30. Ellis NA, Huo D, Yildiz O, et al. MDM2 SNP309 and TP53 Arg72Pro in- bone marrow transplantation. Blood 1996;87:3633–3639. teract to alter therapy-related acute myeloid leukemia susceptibility. Blood 2. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone 2008;112:741–749. marrow transplantation for leukemia or aplastic anemia. N Engl J Med 31. Casorelli I, Offman J, Mele L, et al. Drug treatment in the development 1989;321:784–789. of mismatch repair defective acute leukemia and myelodysplastic syndrome. 3. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow DNA Repair (Amst) 2003;2:547–559. transplantation. N Engl J Med 1997;336:897–904. 32. Seedhouse CH, Das-Gupta EP, Russell NH. Methylation of the hMLH1 4. Krishnan A, Bhatia S, Slovak ML, et al. Predictors of therapy-related leuke- promoter and its association with microsatellite instability in acute myeloid mia and myelodysplasia following autologous transplantation for lymphoma: leukemia. Leukemia 2003;17:83–88. an assessment of risk factors. Blood 2000;95:1588–1593. 33. Seedhouse C, Faulkner R, Ashraf N, et al. Polymorphisms in genes involved 5. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodg- in homologous recombination repair interact to increase the risk of develop- kin’s disease after allogeneic bone marrow transplantation. J Clin Oncol ing acute myeloid leukemia. Clin Cancer Res 2004;10:2675–2680. 1999;17:3122–3127. 34. Matullo G, Palli D, Peluso M, et al. XRCC1, XRCC3, XPD gene polymor- 6. Rizzo JD, Curtis RE, Socie G, et al. Solid cancers after allogeneic hemato- phisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. poietic cell transplantation. Blood 2009;113:1175–1183. Carcinogenesis 2001;22:1437–1445. 7. Leisenring W, Friedman DL, Flowers ME, et al. Nonmelanoma skin and 35. Au WW, Salama SA, Sierra-Torres CH. Functional characterization of poly- mucosal cancers after hematopoietic cell transplantation. J Clin Oncol morphisms in DNA repair genes using cytogenetic challenge assays. Environ 2006;24:1119–1126. Health Perspect 2003;111:1843–1850. 8. Schwartz JL, Kopecky KJ, Mathes RW, et al. Basal cell skin cancer after 36. Seedhouse C, Bainton R, Lewis M, et al. The genotype distribution of the total-body irradiation and hematopoietic cell transplantation. Radiat Res XRCC1 gene indicates a role for base excision repair in the development of 2009;171:155–163. therapy-related acute myeloblastic leukemia. Blood 2002;100:3761–3766. 9. Friedman DL, Rovo A, Leisenring W, et al. Increased risk of breast can- 37. Allan JM, Smith AG, Wheatley K, et al. Genetic variation in XPD predicts cer among survivors of allogeneic hematopoietic cell transplantation: a treatment outcome and risk of acute myeloid leukemia following chemo- report from the FHCRC and the EBMT-Late Effect Working Party. Blood therapy. Blood 2004;104:3872–3877. 2008;111:939–944. 38. Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening 10. Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma af- precedes development of therapy-related myelodysplasia or acute myelog- ter hematopoietic stem-cell transplantation: an EBMT Late Effects Working enous leukemia after autologous transplantation for lymphoma. J Clin Oncol Party Study. J Clin Oncol 2007;25:2449–2454. 2009;27:791–798. 11. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow trans- 39. Hackett JA, Feldser DM, Greider CW. Telomere dysfunction increases muta- plantation. J Clin Oncol 2001;19:464–471. tion rate and genomic instability. Cell 2001;106:275–286. 12. Witherspoon RP, Deeg HJ. Allogeneic bone marrow transplantation for 40. Voermans C, Kooi ML, Rodenhuis S, et al. In vitro migratory capacity of secondary leukemia or myelodysplasia. Haematologica 1999;84:1085–1087. CD34+ cells is related to hematopoietic recovery after autologous stem cell 13. Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of au- transplantation. Blood 2001;97:799–804. tologous hematopoietic-cell transplantation: report from the Bone Marrow 41. Dittel BN, LeBien TW. Reduced expression of vascular cell adhesion mol- Transplant Survivor Study. Blood 2005;105:4215–4222. ecule-1 on bone marrow stromal cells isolated from marrow transplant recipi- 14. Vardiman JW, Harris NL, Brunning RD. The World Health Organiza- ents correlates with a reduced capacity to support human B lymphopoiesis in tion (WHO) classification of the myeloid neoplasms.Blood 2002;100: vitro. Blood 1995;86:2833–2841. 2292–2302. 42. Domenech J, Roingeard F, Herault O, et al. Changes in the functional ca- 15. Pedersen-Bjergaard J, Andersen MK, Christiansen DH, et al. Genetic path- pacity of marrow stromal cells after autologous bone marrow transplantation. ways in therapy-related myelodysplasia and acute myeloid leukemia. Blood Leuk Lymphoma 1998;29:533–546. 2002;99:1909–1912. 43. Cachaco AS, Carvalho T, Santos AC, et al. TNF-alpha regulates the effects 16. Gilliland DG, Gribben JG. Evaluation of the risk of therapy-related MDS/ of irradiation in the mouse bone marrow microenvironment. PLoS One AML after autologous stem cell transplantation. Biol Blood Marrow Trans- 2010;5:e8980. plant 2002;8:9–16. 44. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction 17. Friedberg JW, Neuberg D, Stone RM, et al. Outcome in patients with myelo- induces myelodysplasia and secondary leukaemia. Nature 2010;464:852– dysplastic syndrome after autologous bone marrow transplantation for non- 857. Hodgkin’s lymphoma. J Clin Oncol 1999;17:3128–3135. 45. Yeoh EJ, Williams K, Patel S, et al. Expression profiling of pediatric acute 18. Metayer C, Curtis RE, Vose J, et al. Myelodysplastic syndrome and acute lymphoblastic leukemia (ALL) blasts at diagnosis accurately predicts both myeloid leukemia after autotransplantation for lymphoma: a multicenter the risk of relapse and of developing therapy-induced acute myelogenous case-control study. Blood 2003;101:2015–2023. leukemia (AML). Blood 2001;98:433A. 19. Bhatia R, Van Heijzen K, Palmer A, et al. Longitudinal assessment of hema- 46. Qian Z, Fernald AA, Godley LA, et al. Expression profiling of CD34+ topoietic abnormalities after autologous hematopoietic cell transplantation hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-relat- for lymphoma. J Clin Oncol 2005;23:6699–6711. ed acute myeloid leukemia. Proc Natl Acad Sci U S A 2002;99:14925–14930. 20. Graubert TA, Payton MA, Shao J, et al. Integrated genomic analysis impli- 47. Li L, Li M, Sun CL, et al. Altered hematopoietic cell gene expression pre- cates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo cedes development of therapy-related myelodysplasia/acute myeloid leuke- myelodysplastic syndromes pathogenesis. PLoS One 2009;4:e4583. mia and identifies patients at risk.Cancer Cell 2011;20:591–605. 21. Lane SW, Sykes SM, Al-Shahrour F, et al. The Apc(min) mouse has altered 48. Armand P, Kim HT, DeAngelo DJ, et al. Impact of cytogenetics on outcome hematopoietic stem cell function and provides a model for MPD/MDS. of de novo and therapy-related AML and MDS after allogeneic transplanta- Blood 2010;115:3489–3497. tion. Biol Blood Marrow Transplant 2007;13:655–664. 22. Wong JC, Zhang Y, Lieuw KH, et al. Use of chromosome engineering to 49. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow model a segmental deletion of chromosome band 7q22 found in myeloid transplantation for therapy-related myelodysplastic syndrome and acute my- malignancies. Blood 2010;115:4524–4532. eloid leukemia: a long-term study of 70 patients-report of the French society 23. Downing JR. AML1/CBFbeta transcription complex: its role in normal of bone marrow transplantation. J Clin Oncol 2000;18:963–971. hematopoiesis and leukemia. Leukemia 2001;15:664–665. 50. Litzow MR, Tarima S, Perez WS, et al. Allogeneic transplantation for therapy- 24. Qian Z, Joslin JM, Tennant TR, et al. Cytogenetic and genetic pathways in related myelodysplastic syndrome and acute myeloid leukemia. Blood 2010; therapy-related acute myeloid leukemia. Chem Biol Interact 2010;184:50. 115:1850–1857. 25. Libura J, Slater DJ, Felix CA, et al. Therapy-related acute myeloid leu- 51. Lillington DM, Micallef IN, Carpenter E, et al. Detection of chromosome kemia-like MLL rearrangements are induced by etoposide in primary abnormalities pre-high-dose treatment in patients developing therapy-related human CD34+ cells and remain stable after clonal expansion. Blood myelodysplasia and secondary acute myelogenous leukemia after treatment 2005;105:2124–2131. for non-Hodgkin’s lymphoma. J Clin Oncol 2001;19:2472–2481. 26. Side LE, Curtiss NP, Teel K, et al. RAS, FLT3, and TP53 mutations in ther- 52. Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoprolif- apy-related myeloid malignancies with abnormalities of chromosomes 5 and erative disorders after allogeneic hematopoietic cell transplantation. Blood 7. Genes Chromosomes Cancer 2004;39:217–223. 2009;113:4992–5001. 27. Knight JA, Skol AD, Shinde A, et al. Genome-wide association study to iden- 53. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative dis- tify novel loci associated with therapy-related myeloid leukemia susceptibil- orders after bone marrow transplantation: a multi-institutional study. Blood ity. Blood 2009;113:5575–5582. 1999;94:2208–2216. 28. Funk RK, Maxwell TJ, Izumi M, et al. Quantitative trait loci associated with 54. Luo L, Zhang L, Cai B, et al. Post-transplant lymphoproliferative disease after susceptibility to therapy-related acute murine promyelocytic leukemia in allogeneic hematopoietic stem cell transplantation: a single-center experi- hCG-PML/RARA transgenic mice. Blood 2008;112:1434–1442. ence. Ann Transplant 2014;19:6–12. 29. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-trans- 55. Heslop HE, Ng CY, Li C, et al. Long-term restoration of immunity against ferase P1 is associated with susceptibility to chemotherapy-induced leuke- Epstein-Barr virus infection by adoptive transfer of gene-modified virus- mia. Proc Natl Acad Sci U S A 2001;98:11592–11597. specific T lymphocytes. Nat Med 1996;2:551–555.

Devita_References.indd 428 10/23/14 4:22 AM Chapter 118 References R429

56. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific 68. Socie G, Rizzo JD. Second solid tumors: screening and management guide- T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. lines in long-term survivors after allogeneic stem cell transplantation. Semin Lancet 1995;345:9–13. Hematol 2012;49:4–9. 57. van Esser JW, Niesters HG, van der Holt B, et al. Prevention of Epstein-Barr 69. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on virus-lymphoproliferative disease by molecular monitoring and preemptive the development of squamous-cell cancers after hematopoietic stem-cell trans- rituximab in high-risk patients after allogeneic stem cell transplantation. plantation: an international case-control study. Blood 2005;105:3802–3811. Blood 2002;99:4364–4369. 70. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and 58. Meerbach A, Wutzler P, Hafer R, et al. Monitoring of Epstein-Barr virus load mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl after hematopoietic stem cell transplantation for early intervention in post- J Med 2003;348:1625–1638. transplant lymphoproliferative disease. J Med Virol 2008;80:441–454. 71. Ness KK, Bhatia S, Baker KS, et al. Performance limitations and participation 59. Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein Barr restrictions among childhood cancer survivors treated with hematopoietic virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell transplantation: the bone marrow transplant survivor study. Arch stemcell recipients: a comprehensive review of reported cases. Transpl Infect Pediatr Adolesc Med 2005;159:706–713. Dis 2009;11:383–392. 72. Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host dis- 60. Majhail NS, Brazauskas R, Rizzo JD, et al. Secondary solid cancers after allo- ease on the health status of hematopoietic cell transplantation survivors: a geneic hematopoietic cell transplantation using busulfan-cyclophosphamide report from the Bone Marrow Transplant Survivor Study. Blood 2006;108: conditioning. Blood 2011;117:316–322. 2867–2873. 61. Faber P, Fisch P, Waterhouse M, et al. Frequent genomic alterations in epi- 73. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and car- thelium measured by microsatellite instability following allogeneic hemato- diovascular events in survivors of hematopoietic cell transplantation: a re- poietic cell transplantation in humans. Blood 2006;107:3389–3396. port from the bone marrow transplantation survivor study. Blood 2007; 62. Strong LC, Stine M, Norsted TL. Cancer in survivors of childhood soft tissue 109:1765–1772. sarcoma and their relatives. J Natl Cancer Inst 1987;79:1213–1220. 74. Baker KS, Chow E, Goodman P, et al. Adverse impact of hematopoietic 63. Wong FL, Boice JD Jr, Abramson DH, et al. Cancer incidence after retino- cell transplantation (HCT) on body composition and insulin resistance is blastoma. Radiation dose and sarcoma risk. JAMA 1997;278:1262–1267. associated with increased cardiovascular risk. Biol Blood Marrow Transplant 64. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guide- 2011;17:S174–S175. lines for pediatric cancer: The Children’s Oncology Group long-term follow- 75. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or mar- up guidelines from the Children’s Oncology Group Late Effects Committee row stem-cell transplantation in children and adults: incidence and risk fac- and Nursing Discipline. J Clin Oncol 2004;22:4979–4990. tors. J Clin Oncol 2003;21:1352–1358. 65. Majhail NS, Rizzo JD, Lee SJ, et al. Recommended screening and preventive 76. Shimada K, Yokozawa T, Atsuta Y, et al. Solid tumors after hematopoietic practices for long-term survivors after hematopoietic cell transplantation. stem cell transplantation in Japan: incidence, risk factors and prognosis. Bone Bone Marrow Transplant 2012;47:337–341. Marrow Transplant 2005;36:115–121. 66. Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer So- 77. Gallagher G, Forrest DL. Second solid cancers after allogeneic hematopoi- ciety guidelines for the early detection of cancer. CA Cancer J Clin 2002; etic stem cell transplantation. Cancer 2007;109:84–92. 52:8–22. 78. Socie G, Curtis RE, Deeg HJ, et al. New malignant diseases after alloge- 67. Carlson RW, McCormick B. Update: NCCN breast cancer Clinical Practice neic marrow transplantation for childhood acute leukemia. J Clin Oncol Guidelines. J Natl Compr Canc Netw 2005;3:S7–S11. 2000;18:348–357.

Devita_References.indd 429 10/23/14 4:22 AM